Dimensional Fund Advisors LP Cuts Stake in Hims & Hers Health, Inc. $HIMS

Key Points

• Dimensional Fund Advisors cut its Hims & Hers Health stake by 39.2% in the first quarter, selling 424,976 shares and retaining 660,241 shares valued at approximately $13.7 million. Institutional investors collectively own 63.52% of the company.
• Hims & Hers reported a quarterly loss of $0.40 per share, missing the $0.04 consensus estimate, while revenue rose 3.8% year over year to $608.1 million, slightly below expectations.
• Analyst sentiment remains mixed, with a consensus “Hold” rating and an average price target of $31.43; HIMS recently opened at $31.58 after trading between $13.74 and $65.30 over the past year.

Dimensional Fund Advisors LP reduced its position in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 39.2% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 660,241 shares of the company's stock after selling 424,976 shares during the quarter. Dimensional Fund Advisors LP owned 0.29% of Hims & Hers Health worth $13,707,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in HIMS. Flagship Harbor Advisors LLC purchased a new position in Hims & Hers Health during the 4th quarter valued at about $28,000. Binnacle Investments Inc bought a new stake in shares of Hims & Hers Health in the 3rd quarter valued at about $28,000. Bogart Wealth LLC lifted its position in shares of Hims & Hers Health by 235.8% in the 4th quarter. Bogart Wealth LLC now owns 900 shares of the company's stock worth $29,000 after purchasing an additional 632 shares during the period. Geneos Wealth Management Inc. purchased a new stake in shares of Hims & Hers Health in the 1st quarter worth approximately $30,000. Finally, Greenline Wealth Management LLC bought a new position in shares of Hims & Hers Health during the fourth quarter valued at approximately $36,000. 63.52% of the stock is owned by hedge funds and other institutional investors.

Hims & Hers Health Stock Performance

HIMS stock opened at $31.58 on Friday. Hims & Hers Health, Inc. has a one year low of $13.74 and a one year high of $65.30. The firm has a market cap of $7.31 billion, a price-to-earnings ratio of -350.89, a PEG ratio of 88.90 and a beta of 2.40. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.56 and a current ratio of 1.69. The firm has a 50-day simple moving average of $31.86 and a two-hundred day simple moving average of $26.10.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.04 by ($0.44). Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.The firm had revenue of $608.10 million during the quarter, compared to analysts' expectations of $616.84 million. During the same period in the previous year, the firm earned $0.20 EPS. The firm's quarterly revenue was up 3.8% on a year-over-year basis. On average, equities analysts forecast that Hims & Hers Health, Inc. will post 0.03 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on HIMS shares. Barclays lifted their price objective on shares of Hims & Hers Health from $29.00 to $39.00 and gave the company an "overweight" rating in a report on Wednesday, June 17th. Wall Street Zen lowered Hims & Hers Health from a "hold" rating to a "sell" rating in a report on Saturday, May 9th. Weiss Ratings cut Hims & Hers Health from a "hold (c)" rating to a "sell (d)" rating in a research report on Tuesday, May 12th. Jefferies Financial Group set a $24.50 price target on Hims & Hers Health in a report on Tuesday, May 12th. Finally, Zacks Research raised Hims & Hers Health from a "strong sell" rating to a "hold" rating in a research report on Monday, July 13th. Four research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $31.43.

Insiders Place Their Bets

In other news, insider Irene Becklund sold 7,573 shares of the firm's stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $30.25, for a total value of $229,083.25. Following the completion of the sale, the insider owned 11,280 shares of the company's stock, valued at $341,220. This trade represents a 40.17% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Oluyemi Okupe sold 18,197 shares of the business's stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $34.03, for a total value of $619,243.91. Following the transaction, the chief financial officer owned 284,321 shares in the company, valued at approximately $9,675,443.63. This trade represents a 6.02% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 83,126 shares of company stock valued at $2,711,339. 11.76% of the stock is currently owned by company insiders.

Hims & Hers Health Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients' doorsteps.

The company's product portfolio addresses key areas of men's and women's health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.

Want to see what other hedge funds are holding HIMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hims & Hers Health, Inc. (NYSE:HIMS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source